中华眼科杂志
中華眼科雜誌
중화안과잡지
Chinese Journal of Ophthalmology
2013年
6期
490-494
,共5页
曾婧%闫媛媛%丁小燕%刘冉%李加青
曾婧%閆媛媛%丁小燕%劉冉%李加青
증청%염원원%정소연%류염%리가청
中心性浆液性脉络膜视网膜病变%卟啉类%光化学疗法%脉络膜%体层摄影术,光学相干
中心性漿液性脈絡膜視網膜病變%卟啉類%光化學療法%脈絡膜%體層攝影術,光學相榦
중심성장액성맥락막시망막병변%계람류%광화학요법%맥락막%체층섭영술,광학상간
Central serous chorioretinopathy%Porphyrins%Photochemotherapy%Choroid%Tomography,optical coherence
目的 观察慢性中心性浆液性脉络膜视网膜病变(CSC)患者半剂量维替泊芬光动力疗法(PDT)治疗前、后的脉络膜厚度变化特点.方法 系列病例研究.2010年10月至2011年10月在中山大学中山眼科中心就诊的30例(35只眼)CSC患者入选本研究.所有患者均接受荧光素眼底血管造影(FFA)检查、吲哚氰绿血管造影检查(ICGA)及相干光断层扫描(OCT),被确诊为慢性CSC.所有患者接受PDT治疗,并于治疗前及治疗后1、3、6个月采用频域OCT加强深度成像测定黄斑中心凹下脉络膜厚度(SFCT)及距黄斑中心凹1.5 mm处上、下、鼻、颞四方位脉络膜厚度.治疗前、后各时间点脉络膜厚度的比较采用单因素重复测量方差分析,进一步两两比较采用LSD-t检验.结果 30例(35只眼)慢性CSC患者中,男性26例,女性4例,男女比例为6.5:1;年龄33 ~ 66岁.所有患眼治疗前平均SFCT值为(435.54±102.91) μm,PDT治疗后1、3、6个月SFCT分别为(373.63±106.01)、(360.69±111.06)、(369.00±108.12) μm,均较治疗前明显降低(F=108.34,P<0.01);6个月时后极部脉络膜厚度均值较3个月时有所增加,但差异无统计学意义(LSD-t检验:P >0.05).其他4个测量点脉络膜厚度变化趋势与SFCT一致.结论 慢性CSC患者半剂量维替泊芬PDT治疗后6个月内后极部脉络膜厚度较治疗前降低.
目的 觀察慢性中心性漿液性脈絡膜視網膜病變(CSC)患者半劑量維替泊芬光動力療法(PDT)治療前、後的脈絡膜厚度變化特點.方法 繫列病例研究.2010年10月至2011年10月在中山大學中山眼科中心就診的30例(35隻眼)CSC患者入選本研究.所有患者均接受熒光素眼底血管造影(FFA)檢查、吲哚氰綠血管造影檢查(ICGA)及相榦光斷層掃描(OCT),被確診為慢性CSC.所有患者接受PDT治療,併于治療前及治療後1、3、6箇月採用頻域OCT加彊深度成像測定黃斑中心凹下脈絡膜厚度(SFCT)及距黃斑中心凹1.5 mm處上、下、鼻、顳四方位脈絡膜厚度.治療前、後各時間點脈絡膜厚度的比較採用單因素重複測量方差分析,進一步兩兩比較採用LSD-t檢驗.結果 30例(35隻眼)慢性CSC患者中,男性26例,女性4例,男女比例為6.5:1;年齡33 ~ 66歲.所有患眼治療前平均SFCT值為(435.54±102.91) μm,PDT治療後1、3、6箇月SFCT分彆為(373.63±106.01)、(360.69±111.06)、(369.00±108.12) μm,均較治療前明顯降低(F=108.34,P<0.01);6箇月時後極部脈絡膜厚度均值較3箇月時有所增加,但差異無統計學意義(LSD-t檢驗:P >0.05).其他4箇測量點脈絡膜厚度變化趨勢與SFCT一緻.結論 慢性CSC患者半劑量維替泊芬PDT治療後6箇月內後極部脈絡膜厚度較治療前降低.
목적 관찰만성중심성장액성맥락막시망막병변(CSC)환자반제량유체박분광동력요법(PDT)치료전、후적맥락막후도변화특점.방법 계렬병례연구.2010년10월지2011년10월재중산대학중산안과중심취진적30례(35지안)CSC환자입선본연구.소유환자균접수형광소안저혈관조영(FFA)검사、신타청록혈관조영검사(ICGA)급상간광단층소묘(OCT),피학진위만성CSC.소유환자접수PDT치료,병우치료전급치료후1、3、6개월채용빈역OCT가강심도성상측정황반중심요하맥락막후도(SFCT)급거황반중심요1.5 mm처상、하、비、섭사방위맥락막후도.치료전、후각시간점맥락막후도적비교채용단인소중복측량방차분석,진일보량량비교채용LSD-t검험.결과 30례(35지안)만성CSC환자중,남성26례,녀성4례,남녀비례위6.5:1;년령33 ~ 66세.소유환안치료전평균SFCT치위(435.54±102.91) μm,PDT치료후1、3、6개월SFCT분별위(373.63±106.01)、(360.69±111.06)、(369.00±108.12) μm,균교치료전명현강저(F=108.34,P<0.01);6개월시후겁부맥락막후도균치교3개월시유소증가,단차이무통계학의의(LSD-t검험:P >0.05).기타4개측량점맥락막후도변화추세여SFCT일치.결론 만성CSC환자반제량유체박분PDT치료후6개월내후겁부맥락막후도교치료전강저.
Objective To observe the choroidal thickness in eyes with chronic central serous chorioretinopathy(CSC) after half-dose photodynamic therapy (PDT).Methods Case series study.Consecutive 30 patients (35 eyes) with chronic CSC admitted from October 2010 to October 2011 in Zhongshan Ophthalmic Center were recruited in this study.Optical coherence tomography(OCT),fundus fluorescein angiography,indocyanine green angiography (ICGA) were performed in each patient to confirm the diagnosis.ICGA-guided PDT was performed in each patient.Choroidal thickness at subfoveal and 1500 μm superior,inferior,nasal and temporal to the fovea were measured before PDT,1,3 and 6 months after PDT using enhanced depth imaging OCT.Data were analyzed with one-way repeated measures ANOVA and LSD-t test when pairwise comparison was needed.Results Thirty patients,aged from 33 to 66 years old,including 26 males and 4 females (gender ratio 6.5:1) were recruited.Subfoveal choroidal thickness (SFCT) in chronic CSC eyes was (435.54 ± 102.91) μm at baseline,which decreased significantly to (373.63 ±106.01) μm,(360.69 ± 111.06) μm and (369.00 ± 108.12) μm at 1 month,3 months and 6 months after PDT respectively (F =108.34,P < 0.01).At 6 months after PDT,SFCT was slightly thicker than that at the 3rd month,but no statistical significance was noted(LSD-t test:P > 0.05).The changing trends of choroidal thickness at the other 4 measuring points were similar to that of the SFCT.Conclusion Choroidal thickness is reduced within 6 months post-PDT in chronic CSC eyes.(Chin J Ophthalmol,2013,49:490-494)